Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials

AIM: To investigate the efficacy and safety of initiating insulin degludec/liraglutide (IDegLira) in patients with type 2 diabetes (T2D) who had discontinued pretrial sulphonylureas (SUs) or dipeptidyl peptidase‐4 inhibitors (DPP4is) versus patients not previously treated with these regimens. MATERI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Janez, Andrej, Őrsy, Petra, Stachlewska, Karolina, Salvesen‐Sykes, Karen, Billings, Liana K., Philis‐Tsimikas, Athena
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079143/
https://ncbi.nlm.nih.gov/pubmed/31858673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados